chufangao/CTO huggingface dataset:
Clinical trial NCT03019185: A Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients With Alport Syndrome - CARDINAL
Official title: A Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients With Alport Syndrome
Acronym: CARDINAL
Sponsor: Biogen (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: COMPLETED 
Enrollment: 187.0 (ACTUAL)
Number of arms: 3.0
Start date: 2017-03-02
Primary completion date: 2020-10-06
Completion date: 2020-10-30
Baseline population: All enrolled patients
Plan to share individual participant data: YES
IPD sharing description: In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on https://www.biogentrialtransparency.com/
Clinical trial NCT04344600: Peginterferon Lambda-1a for the Prevention and Treatment of SARS-CoV-2 (COVID-19) Infection
Official title: Peginterferon Lambda-1a for the Prevention and Treatment of SARS-CoV-2 Infection
Acronym: PROTECT
Sponsor: Johns Hopkins University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Single center study with low enrollment
Enrollment: 6.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-06-29
Primary completion date: 2021-09-24
Completion date: 2021-09-24
Plan to share individual participant data: NO
Clinical trial NCT01460160: Pediatric Philadelphia Positive Acute Lymphoblastic Leukemia
Official title: A Phase 2 Multi-Center, Historically Controlled Study of Dasatinib Added to Standard Chemotherapy in Pediatric Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Sponsor: Bristol-Myers Squibb (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 106.0 (ACTUAL)
Number of arms: 1.0
Start date: 2012-04-13
Primary completion date: 2017-05-28
Completion date: 2021-06-01
Clinical trial NCT04834349: Re-irradiation With NBTXR3 in Combination With Pembrolizumab for the Treatment of Inoperable Locoregional Recurrent Head and Neck Squamous Cell Cancer
Official title: A Phase II Study of Reirradiation With NBTXR3 in Patients With Inoperable Locoregional Recurrent Head and Neck Squamous Cell Carcinoma
Sponsor: M.D. Anderson Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: No participants were enrolled
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-03-09
Primary completion date: 2022-11-21
Completion date: 2022-11-21
Clinical trial NCT04261335: The Clinical Trial of CL2020 Cells for Neonatal Hypoxic Ischemic Encephalopathy
Official title: The Evaluation of Safety and Tolerability of CL2020 in Neonatal Hypoxic Ischemic Encephalopathy Patients With Therapeutic Hypothermia in the Dose Escalation Clinical Trial
Acronym: SHIELD
Sponsor: Nagoya University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 9.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-03-04
Primary completion date: 2021-09-29
Completion date: 2022-12-12
Plan to share individual participant data: NO
Clinical trial NCT04096573: Efficacy and Safety of LC51-0255 in Subjects With Ulcerative Colitis
Official title: A Phase 2, Multi Center, Randomized, Placebo Controlled Parallel Group Study to Evaluate the Clinical Efficacy and Safety of LC51 0255 in Subjects With Moderately to Severely Active Ulcerative Colitis
Sponsor: LG Chem (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: company decision
Enrollment: 0.0 (ACTUAL)
Number of arms: 4.0
Start date: 2020-04-30
Primary completion date: 2021-11-30
Completion date: 2022-08-31
Plan to share individual participant data: UNDECIDED
Clinical trial NCT04178967: Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis
Official title: A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate to Severe Atopic Dermatitis.
Acronym: ADvocate2
Sponsor: Eli Lilly and Company (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 445.0 (ACTUAL)
Number of arms: 4.0
Start date: 2019-10-29
Primary completion date: 2021-07-12
Completion date: 2022-04-28
Baseline population: All randomized participants, even if the participant does not take the assigned treatment, does not receive the correct treatment, or otherwise does not follow the protocol.
Limitations and caveats: One investigational site with eighteen participants was excluded from analysis due to GCP issues.
Plan to share individual participant data: YES
IPD sharing description: Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
IPD time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
IPD access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Clinical trial NCT03573921: Gastrografin for Treating Small Bowel Obstruction in Children
Official title: The Therapeutic Role of Gastrografin for Treating Small Bowel Obstruction in Children: A Multi-Centre Canadian Prospective Study
Sponsor: Lawson Health Research Institute (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: TERMINATED 
Why stopped: Poor recruitment to date.
Enrollment: 2.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-09-01
Primary completion date: 2022-12-19
Completion date: 2022-12-19
Clinical trial NCT03798366: A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Systemic Sclerosis
Official title: A Phase 2a, Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy, Safety, and Tolerability of Orally Administered GLPG1690 for 24 Weeks in Subjects With Systemic Sclerosis
Acronym: NOVESA
Sponsor: Galapagos NV (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 33.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-01-14
Primary completion date: 2020-05-21
Completion date: 2020-06-22
Baseline population: Full analysis set (FAS) consisted of all randomized participants who received at least 1 dose of investigational product.
Limitations and caveats: This was a proof-of-concept study not sized or powered to confirm any treatment effect.
Clinical trial NCT04585789: A Study to Assess Intrahepatic and Peripheral Changes of Immunologic and Virologic Markers in Chronic Hepatitis B Virus Infection
Official title: A Phase 2 Randomized, Open-label, Parallel-group, Multicenter Study to Assess Intrahepatic and Peripheral Changes of Immunologic and Virologic Markers in Response to Combination Regimens Containing JNJ-73763989 and Nucleos(t)Ide Analog With or Without JNJ-56136379 in Patients With Chronic Hepatitis B Virus Infection
Acronym: INSIGHT
Sponsor: Janssen Research & Development, LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 24.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-03-11
Primary completion date: 2023-02-08
Completion date: 2024-01-09
Plan to share individual participant data: YES
IPD sharing description: The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency.~As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Clinical trial NCT03618823: Non-opioids for Analgesia After Adenotonsillectomy in Children
Official title: Randomized Clinical Trial of Non-Opioid Pain Medications After Adenotonsillectomy
Sponsor: University of Pittsburgh (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Early termination due to COVID-19 cases and cancelled surgeries.
Enrollment: 268.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-10-25
Primary completion date: 2020-05-18
Completion date: 2020-05-18
Limitations and caveats: Early termination due to COVID-19 cases and cancelled surgeries.
Plan to share individual participant data: YES
IPD sharing description: Only co-investigators as listed under the University of Pittsburgh IRB (Institutional Review Board) protocol for this study will have access to all data and analysis. Data will be shared via UPMC-associated OneDrive and will only be shared between these investigators.
IPD time frame: All data will be maintained for at least 7 years or until the child turns 23 per University of Pittsburgh policy.
IPD access criteria: All data will be shared as-needed for analysis amongst the listed co-investigators in the University of Pittsburgh IRB protocol for this study. It will be stored on the UPMC OneDrive.
Clinical trial NCT02831933: Trial of Radiation and Gene Therapy Before Nivolumab for Metastatic Non-Small Cell Lung Carcinoma and Uveal Melanoma
Official title: ENSIGN: Phase II Window of Opportunity Trial of Stereotactic Body Radiation Therapy and In Situ Gene Therapy Followed by Nivolumab in Metastatic Squamous or Non-Squamous Non-Small Cell Lung Carcinoma and Metastatic Uveal Melanoma
Acronym: ENSIGN
Sponsor: The Methodist Hospital Research Institute (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Lack of funding
Enrollment: 11.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-02-15
Primary completion date: 2020-11-05
Completion date: 2020-11-05
Plan to share individual participant data: YES
IPD sharing description: Data and materials on human subjects will be shared with other eligible investigators through appropriate means in accordance with the NIH policy on Sharing Research Data (NIH Guide, February 26, 2003). Data will be also shared with the funding agency and regulatory agencies as required. Data will be shared with other investigators within the limits of HIPAA and other patient confidentiality requirements. This will generally require removal of all patient identifiers for all source documents and the use of arbitrarily assigned one-way identifiers. In some cases, requestors will be asked to sign a formal data sharing agreement that will provide for a commitment to use data only for research purposes and not to identify individuals, keep the data secure, and destroy or return data after analyses are complete. Prior approval will be obtained from collaborating investigators, research sponsors, and/or other stake-holders before sharing if proprietary information or products are involved.
Clinical trial NCT05614648: Sciatica Epidural Radiculopathy Experimental New Interventional TherapY Clonidine Micropellet
Official title: A Phase 3, Prospective, Multicenter, Randomized, Double-blind, Sham-controlled Study of the Efficacy and Safety of STX-015 in the Treatment of Pain Associated With Lumbosacral Radiculopathy
Acronym: SERENITY CM
Sponsor: Sollis Therapeutics, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Loss of funding- Study halted prematurely and will not resume; participants are no longer being examined or receiving intervention.
Enrollment: 17.0 (ACTUAL)
Number of arms: 2.0
Start date: 2023-06-19
Primary completion date: 2024-03-18
Completion date: 2024-03-30
Plan to share individual participant data: NO
Clinical trial NCT02777385: Pembrolizumab in Combination With Cisplatin and Intensity Modulated Radiotherapy (IMRT) in Head and Neck Cancer
Official title: Randomized, Phase II Study Evaluating Concurrent or Sequential Fixed-Dose Pembrolizumab in Combination With Cisplatin and Intensity Modulated Radiotherapy in Intermediate or High Risk, Previously Untreated, Locally Advanced Head and Neck Cancer
Sponsor: University of Pittsburgh (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 80.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-05-31
Primary completion date: 2023-04-24
Completion date: 2023-05-04
Plan to share individual participant data: NO
Clinical trial NCT03502954: A Study to Investigate the Safety, Tolerability and Pharmacokinetics of ABY-039
Official title: A Phase 1, First-in-human, Randomized, Double Blind, Placebo Controlled, Safety, Tolerability and Pharmacokinetic Study of ABY 039 in Healthy Subjects
Sponsor: Affibody (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Halted prematurely
Enrollment: 66.0 (ACTUAL)
Number of arms: 4.0
Start date: 2018-02-26
Primary completion date: 2020-02-01
Completion date: 2020-03-20
Plan to share individual participant data: NO
Clinical trial NCT03189836: Study of ACTR707 in Combination With Rituximab in Subjects With Relapsed or Refractory B Cell Lymphoma
Official title: Phase 1 Study of ACTR707, an Autologous T Cell Product, in Combination With Rituximab, in Subjects With Relapsed or Refractory CD20+ B Cell Lymphoma
Sponsor: Cogent Biosciences, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Business decision
Enrollment: 26.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-10-04
Primary completion date: 2020-09-21
Completion date: 2020-09-21
Plan to share individual participant data: NO
Clinical trial NCT03923010: A Study of Itraconazole in the Management of Superficial Fungal Infections in India
Official title: Itraconazole in the Management of Superficial Fungal Infections in India. A Pilot Study
Sponsor: Janssen Research & Development, LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Further recruitment not possible due to COVID 19 impact. Hence a decision to close study was taken by the sponsor in Aug 2020
Enrollment: 40.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-08-06
Primary completion date: 2020-03-25
Completion date: 2020-03-27
Plan to share individual participant data: YES
IPD sharing description: The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency.~As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Clinical trial NCT04540848: Post Operative Pain Control for Distal Radius Surgery: Does Exparel Injected at the Surgery Site Improve Postoperative Pain Scores at 24 and 48 Hours ?
Official title: Post Operative Pain Control for Distal Radius Surgery: Does Exparel Injected at the Surgery Site Improve Postoperative Pain Scores at 24 and 48 Hours ?
Sponsor: The University of Texas Health Science Center, Houston (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: Lack of ability to communicate with the study population
Enrollment: 0.0 (ACTUAL)
Number of arms: 3.0
Start date: 2021-03-01
Primary completion date: 2021-11-20
Completion date: 2021-11-20
Plan to share individual participant data: NO
Clinical trial NCT04220125: Preoperative Ketamine and Perioperative Depression
Official title: Preoperative Ketamine as a Strategy to Decrease Perioperative Depression During the Perioperative Period: a Randomized Active Controlled Pilot Study
Sponsor: Northwestern University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: No enrollment
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-09-01
Primary completion date: 2023-02-02
Completion date: 2023-02-02
Plan to share individual participant data: NO
Clinical trial NCT02695641: Reduction of Plasma Free VEGF-A Using Low-dose Bevacizumab in Hemodialysis Patients
Official title: A Phase 0 Study to Evaluate the Pharmacokinetics of Low-dose Bevacizumab and Its Efficacy on Reducing Plasma Free Vascular Endothelial Growth Factor-A (VEGF-A) in Hemodialysis Patients
Sponsor: Mayo Clinic (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: WITHDRAWN 
Why stopped: Unable to enroll patients for the trial.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-08-01
Primary completion date: 2020-08-31
Completion date: 2021-11-30
Plan to share individual participant data: NO
Clinical trial NCT03699462: The Effect of Balanced Crystalloid Versus 5% Albumin on Endothelial Glycocalyx Degradation in Patients Undergoing Off-pump Coronary Artery Bypass Surgery
Official title: The Effect of Balanced Crystalloid Versus 5% Albumin on Endothelial Glycocalyx Degradation in Patients Undergoing Off-pump Coronary Artery Bypass Surgery
Sponsor: Yonsei University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 106.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-11-13
Primary completion date: 2020-10-17
Completion date: 2020-10-17
Plan to share individual participant data: NO
Clinical trial NCT04681027: Safety, Tolerability, Effectiveness, and Pharmacokinetic Data in Opioid-experienced Children
Official title: A Multicenter Study of the Safety, Tolerability, Effectiveness, and Pharmacokinetics of Oxymorphone HCL Extended-Release Tablets in Pediatric Subjects Requiring an Around-The-Clock Opioid for an Extended Period of Time
Sponsor: Endo Pharmaceuticals (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: SUSPENDED 
Why stopped: Study Suspended 06Feb2020 per FDA Request
Enrollment: 15.0 (ACTUAL)
Number of arms: 2.0
Start date: 2013-03-11
Primary completion date: 2017-04-04
Completion date: 2021-01-31
Plan to share individual participant data: YES
Clinical trial NCT03586687: Osteoarthritis Shoulder Injection Study
Official title: Clinical Outcomes Following Randomization of Steroid Concentration in Patients With Glenohumeral Osteoarthritis
Sponsor: Milton S. Hershey Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: insufficient rate of accrual
Enrollment: 19.0 (ACTUAL)
Number of arms: 3.0
Start date: 2018-07-13
Primary completion date: 2021-09-28
Completion date: 2021-09-28
Limitations and caveats: Target enrollment was not reached due to the COVID pandemic. The secondary outcome measure involving SPADI at 12 months were not collected due to COVID pandemic.
Plan to share individual participant data: NO
Clinical trial NCT03386955: BPI-7711 Capsule in Patients With EGFR Mutation T790M Positive Non-small Cell Lung Cancer
Official title: An Open-label, Single Arm, Phase I/IIa Study to Evaluate Safety, Dose Escalation Tolerability, Pharmacokinetics and Antineoplastic Activity of the BPI-7711 Capsule in Patients With EGFR Mutation Advanced or Recurrent NSCLC
Sponsor: Beta Pharma, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: COMPLETED 
Enrollment: 215.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-08-16
Primary completion date: 2021-12-23
Completion date: 2021-12-23
Plan to share individual participant data: NO
Clinical trial NCT04721535: A Study of DWJ1248 in Prevention of COVID-19 Infection After the Exposure of SARS-COV-2
Official title: A Randomized Double-blinded Controlled Clinical Trial of DWJ1248 in Prevention of COVID-19 Infection After the Exposure of SARS-COV-2
Sponsor: Daewoong Pharmaceutical Co. LTD. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Termination of study due to sponsor's internal decision
Enrollment: 9.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-06-07
Primary completion date: 2021-09-23
Completion date: 2021-10-06
Plan to share individual participant data: NO
Clinical trial NCT03652233: Afatinib and Nivolumab as Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
Official title: Afatinib and Nivolumab for Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) Not Previously Treated With Immunotherapy.
Sponsor: Vanderbilt-Ingram Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Low accrual
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-11-02
Primary completion date: 2021-11-30
Completion date: 2022-11-30
Clinical trial NCT06625359: High-dose Chemotherapy with Thiotepa, Busulfan, and Cyclophosphamide Followed by Autologous Stem Cell Transplantation in Central Nervous System Lymphoma
Official title: Efficacy of High-dose Chemotherapy with Thiotepa, Busulfan, and Cyclophosphamide Before Autologous Stem Cell Transplantation in Patients with Primary/secondary Central Nervous System Lymphoma
Sponsor: Seoul National University Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: slow enrollment
Enrollment: 17.0 (ACTUAL)
Number of arms: 1.0
Start date: 2015-06-01
Primary completion date: 2024-09-30
Completion date: 2024-09-30
Plan to share individual participant data: UNDECIDED
IPD sharing description: not determined
Clinical trial NCT03320850: BOTOX® Intravesical Instillation in Participants With Overactive Bladder and Urinary Incontinence
Official title: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Single-treatment, 2-stage, Dose-finding Study Evaluating the Efficacy and Safety of BOTOX® Intravesical Instillation in Participants With Overactive Bladder and Urinary Incontinence
Acronym: APOLLO
Sponsor: Allergan (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 383.0 (ACTUAL)
Number of arms: 8.0
Start date: 2017-10-04
Primary completion date: 2020-07-21
Completion date: 2020-07-21
Baseline population: Stage 1: Safety Analysis Set included all participants who were randomized and treated; Stage 2: Intent-to-treat (ITT) Analysis Set included all randomized participants.
Plan to share individual participant data: YES
IPD sharing description: * Phase II or III trials completed after 2008~* Listed on clinicaltrials.gov or EudraCT~* Have received regulatory approval in the United States and/or European Union (depending on registration plans) in a given indication~* Primary manuscript(s) from the trial have been published~Access to data is contingent upon the following:~* Researcher signs a data use agreement from Allergan~* Data is to be used for non-commercial purposes
Clinical trial NCT04220502: Magic Shave Powder Gold's Affects on the Occurrence of Pseudofolliculitis Barbae
Official title: Depilatory Cream's Affect on the Occurrence of Pseudofolliculitis Barbae
Sponsor: Wayne State University (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: WITHDRAWN 
Why stopped: Unable to recruit
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-08-01
Primary completion date: 2022-05-03
Completion date: 2022-05-03
Plan to share individual participant data: NO
Clinical trial NCT04732429: Study of HST5040 in Subjects With Propionic or Methylmalonic Acidemia
Official title: A Phase 2 Open-label, Dose Escalation Study of HST5040 in Subjects With Propionic or Methylmalonic Acidemia Followed by a Randomized, Double-blind, Placebo-controlled, 2-period Crossover Study and an Open-label, Long-term Extension Study
Acronym: HERO
Sponsor: HemoShear Therapeutics (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: The decision to terminate the study was based on business considerations by the Sponsor.
Enrollment: 26.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-03-15
Primary completion date: 2023-10-20
Completion date: 2023-10-20
Plan to share individual participant data: NO